Alumis (NASDAQ:ALMS) Stock Sees Heavy Put Option Buying

Posted by George Bondi on Oct 12th, 2026

Alumis Inc. (NASDAQ:ALMS – Get Free Report) saw unusually large options trading activity on Monday. Stock traders acquired 10,007 put options on the stock. This is an increase of approximately 446% compared to the average daily volume of 1,832 put options.

Alumis Stock Performance

Shares of NASDAQ ALMS traded up $0.01 during midday trading on Monday, hitting $7.17. The company’s stock had a trading volume of 691,107 shares, compared to its average volume of 2,257,357. Alumis has a 1-year low of $4.37 and a 1-year high of $31.35. The firm’s fifty day moving average price is $15.31 and its 200-day moving average price is $21.22. The firm has a market cap of $928.70 million, a P/E ratio of -1.86 and a beta of -0.38.

Alumis (NASDAQ:ALMS – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.34). The business had revenue of $1.66 million for the quarter, compared to the consensus estimate of $3.65 million. Alumis had a negative net margin of 5,933.46% and a negative return on equity of 93.15%. As a group, research analysts predict that Alumis will post -2.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider David M. Goldstein sold 2,596 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $68,456.52. Following the transaction, the insider owned 30,970 shares of the company’s stock, valued at approximately $816,678.90. This trade represents a 7.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jorn Drappa sold 2,447 shares of Alumis stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $64,527.39. Following the completion of the transaction, the insider owned 56,892 shares of the company’s stock, valued at $1,500,242.04. This trade represents a 4.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 111,084 shares of company stock worth $1,408,493. 33.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Alumis

A number of hedge funds and other institutional investors have recently bought and sold shares of ALMS. BlackRock Inc. bought a new position in shares of Alumis during the second quarter valued at approximately $231,259,000. venBio Partners LLC bought a new position in Alumis during the second quarter valued at approximately $127,429,401. Cormorant Asset Management LP lifted its stake in Alumis by 69.3% in the fourth quarter. Cormorant Asset Management LP now owns 3,635,596 shares of the company’s stock valued at $35,483,000 after acquiring an additional 1,488,200 shares during the last quarter. Octagon Capital Advisors LP lifted its stake in Alumis by 11.9% in the first quarter. Octagon Capital Advisors LP now owns 2,830,700 shares of the company’s stock valued at $62,360,000 after acquiring an additional 300,000 shares during the last quarter. Finally, Jupiter Topco LLC acquired a new stake in Alumis in the second quarter valued at approximately $66,238,000.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Alumis in a report on Friday, October 2nd. Robert W. Baird set a $27.00 target price on Alumis in a research report on Tuesday, September 1st. HC Wainwright reiterated a “buy” rating on shares of Alumis in a report on Monday, October 5th. Morgan Stanley dropped their price target on Alumis from $39.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 2nd. Finally, Citigroup reissued an “overweight” rating on shares of Alumis in a research report on Tuesday, September 1st. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $33.27.

Get Our Latest Research Report on ALMS

Alumis Company Profile

(Get Free Report)

Alumis, Inc is a clinical-stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases. The company’s research centers on selective allosteric inhibitors of tyrosine kinase 2 (TYK2), a protein involved in signaling pathways that regulate inflammation and immune responses.

Alumis’ lead product candidate is ESK-001, an oral, highly selective TYK2 inhibitor being evaluated in inflammatory and autoimmune conditions, including plaque psoriasis, psoriatic arthritis and systemic lupus erythematosus.